Evidence map›Paper›PMID 32494924›Full record

ReviewCurrent atherosclerosis reports2020

Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.

Aliza Hussain, Christie M Ballantyne, Anum Saeed, Salim S Virani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Molecular medicine reports · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Targeting ANGPTL3 by GalNAc-conjugated siRNAMolecular therapy. Nucleic acids · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Aliza HussainDepartment of Medicine, Section of Cardiovascular Research, Baylor College of Medicine, Houston, TX, USA.
Christie M BallantyneDepartment of Medicine, Section of Cardiovascular Research, Baylor College of Medicine, Houston, TX, USA.
Anum SaeedUniversity of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Salim S ViraniDepartment of Medicine, Section of Cardiovascular Research, Baylor College of Medicine, Houston, TX, USA. virani@bcm.edu.
Baylor College of Medicine · USUniversity of Pittsburgh Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review focuses on recent evidence examining the role triglycerides (TG) and triglyceride-enriched lipoproteins (TGRL) play in atherosclerotic cardiovascular disease (ASCVD). It also provides a succinct overview of current and future TG-lowering therapies for ASCVD risk reduction. RECENT

findingsEpidemiological and Mendelian randomization studies have consistently shown that TGRL are strongly associated with ASCVD. REDUCE-IT demonstrated cardiovascular benefit with icosapent ethyl in high-risk patients with hypertriglyceridemia on statin therapy. Polymorphisms in APOC3 and ANGPTL3 are associated with ASCVD and use of RNA-interfering therapies to target these proteins has shown TG lowering in early phase trials. TG and TGRL are causally associated with ASCVD. Lifestyle modifications and statin therapy can lower TG/TGRL and are considered first-line treatment for hypertriglyceridemia. Icosapent ethyl has been shown to reduce residual ASCVD risk in high-risk patients on maximally tolerated statins. Ongoing clinical trials will better define optimal therapy for patients on statins with residual hypertriglyceridemia.

Indexed as

Risk Reduction BehaviorAngiopoietin-Like Protein 3Angiopoietin-like ProteinsApolipoprotein C-IIIAtherosclerosisEicosapentaenoic AcidFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypertriglyceridemiaLipid Regulating AgentsLipoproteinsMaleMiddle AgedPolymorphism, Single NucleotideRNA InterferenceAngiopoietin-Like Protein 3Angiopoietin-like ProteinsANGPTL3 protein, humanAPOC3 protein, humanApolipoprotein C-IIIEicosapentaenoic Acideicosapentaenoic acid ethyl esterHydroxymethylglutaryl-CoA Reductase InhibitorsLipid Regulating AgentsLipoproteinslipoprotein triglycerideTriglyceridesAngiopoietin 3Apolipoprotein C3ASCVDOmega-3 fatty acidsTriglyceride-rich lipoproteinsTriglycerides

Identifiers

PMID32494924
OpenAlexW3029160714

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.